Way Less has actual clinics, takes actual insurance and offers a wider range of weight medications than most of this category. It also advertises semaglutide at $150 a month with an asterisk that, once you follow it, describes a discount engineered to end at almost exactly the point the medication becomes effective.
The Discount Expires When the Dose Starts Working
The headline is semaglutide “starts at $275 $150 monthly”, with the $275 struck through and a note that this is about $37 per injection. The asterisk reads: “Limited-time offer for 0.25 mg and 0.5 mg doses only, valid for the first two months.”
Those two doses, over those two months, are the standard titration schedule. Semaglutide is conventionally started at 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, before escalating further. The discount covers the titration period exactly — and stops at the point you begin moving toward a therapeutic dose.
This matters because those starting doses are chosen for tolerability, not effect. They exist to let the gut adapt. The weight-loss figures everyone quotes come from months at higher doses — roughly 15% mean loss for semaglutide 2.4 mg at 68 weeks. So the advertised price applies to the phase in which the medication is expected to do relatively little, and the price you will actually live with is the $275 one, which appears on screen only with a line through it.
We are not suggesting the offer is hidden — the footnote is there and states the terms plainly, which is better than many competitors manage. The issue is that the terms and the clinical schedule line up so precisely that a shopper comparing headline prices will systematically underestimate what a year costs. At $275 a month, twelve months is $3,300; the $150 figure describes $300 of it.
We have flagged the same shape at Curex, where $49 becomes $199 after the introductory month. The pattern is worth recognising generally: in a treatment that escalates over months, an introductory discount is a discount on the least useful part.
Ozempic and Semaglutide Are Not the Same Line Item
The products are presented as grouped lines: “Ozempic, Wegovy and Semaglutide” under one price, and “Mounjaro, Zepbound and Tirzepatide” under another, with tirzepatide starting at $225.
Grouping them this way collapses a distinction that decides what you actually receive. Ozempic and Wegovy are FDA-approved Novo Nordisk products; “semaglutide” on its own, at these prices, is almost certainly a compounded preparation. At $150 or even $275 a month, nobody is dispensing brand-name Wegovy at cash price.
So the price tells you it is compounded while the product name suggests it might be the brand. That is the single most consequential fact about a GLP-1 purchase, and here it has to be inferred from arithmetic rather than read from the page.
Since the FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage on 21 February 2025, the basis on which these molecules may be compounded has changed — which makes it more important, not less, that a seller states plainly which one it is dispensing. Our compounded versus brand-name guide covers what turns on it. Ask directly, and get the answer before your first injection.
The 3D Scan as a Qualification Route
Way Less offers 3D InBody body composition scanning, and a published patient account describes someone at 174 lb who did not qualify on the scale alone and was then approved on the basis of the scan.
There is a genuinely good argument here, and it deserves stating first. BMI is a crude measure. It cannot distinguish muscle from fat, it misclassifies muscular people as overweight and it misses people carrying high visceral fat at a normal weight. Body composition analysis is more informative than a height-and-weight ratio, and a clinic willing to measure it is doing more than most.
The same mechanism, used the other way, becomes a route to approving people who do not meet the standard threshold. The published eligibility criteria for these medications are BMI-based — broadly 30 and above, or 27 and above with a weight-related condition — and the trials that produced the efficacy and safety data enrolled on that basis.
Both readings are available from what is published, and we cannot tell from the outside which applies in any individual case — that testimonial describes one person whose full clinical picture we do not know, and a clinician may well have had good reasons. What we would say is this: if a scan is what moves you from “not eligible” to “eligible”, that is the moment to ask what specifically about your body composition justifies treatment, and what the evidence is for people in your position. Our GLP-1 eligibility guide sets out the conventional criteria.
Real Clinics, Real Insurance, Real Breadth
Way Less has physical clinics in Oak Brook, Illinois and Merrillville, Indiana. In a category dominated by services that have never seen a patient in person, being somewhere you can walk into is a real difference — weight management involves measurements, blood pressure and physical examination that a video call approximates poorly.
It accepts a long list of insurers — Blue Cross, UnitedHealthcare, Ambetter, Aetna, Cigna, Anthem and Humana among others — which puts it inside a system with credentialing and claims review rather than outside it. Consultations are free, which means you can get an assessment and a price before committing to anything.
The medication menu is unusually broad: alongside the GLP-1s it offers liraglutide, phentermine, Qsymia, Contrave and orlistat. Those older drugs have real evidence behind them and cost a fraction of a GLP-1, and a clinic that stocks them can put someone on an appropriate cheaper option instead of defaulting to the expensive one. Their prices are not published, which is the gap.
Provider Facts
| Medications offered | Semaglutide, tirzepatide and liraglutide, plus phentermine, Qsymia, Contrave and orlistat; brand names are grouped with generic descriptions in single product lines |
|---|---|
| Brand-name or compounded | Not clearly stated - brand names and generic descriptions are listed together, and the advertised prices imply compounded product |
| Consultation process | Free consultation; 3D InBody body composition scanning offered |
| Eligibility | Not published as a BMI threshold; body composition scanning is used in assessment |
| Provider involvement | Clinic-based care at two locations; individual clinician credentials not published |
| Lab requirements | Not published |
| Pharmacy fulfillment | Not published |
| Shipping frequency | Not published - cold chain handling not described |
| Support services | In-person clinic visits with body composition tracking |
| Membership fees | None published - medication pricing is the stated cost |
| Medication fees | Semaglutide advertised at $275 reduced to $150, restricted to 0.25 mg and 0.5 mg doses for the first two months; tirzepatide from $225; other medications not priced |
| Cancellation policy | Not published |
| Refund policy | Not published |
| Insurance | Accepted, including Blue Cross, UnitedHealthcare, Ambetter, Aetna, Cigna, Anthem and Humana |
| HSA/FSA | Not published |
| Availability | Two clinics - Oak Brook, Illinois and Merrillville, Indiana; telehealth availability beyond these not published |
Pros and Cons
Pros
- Physical clinics you can attend in person, in two states
- Accepts a long list of major insurers
- Free consultation before any commitment
- Body composition scanning rather than the scale alone
- Broad menu including cheaper evidence-backed older medications
- Publishes the undiscounted semaglutide price and the offer terms
Cons
- The $150 rate covers only the two titration months, then reverts to $275
- Brand names grouped with generics, so you cannot tell what you would receive
- Never states whether its GLP-1s are compounded or brand-name
- Body composition scanning can function as a route around BMI criteria
- No prices for liraglutide, phentermine, Qsymia, Contrave or orlistat
- No labs, pharmacy, cold chain, refund policy or telehealth detail
Who It May Be Best For
A good fit if you live near Oak Brook or Merrillville and want in-person care with insurance applied, rather than a mail-order subscription.
Especially if a cheaper older medication might suit you — a clinic that stocks phentermine, Qsymia, Contrave and orlistat can offer something other than the most expensive option.
Budget against $275, not $150. The discount ends after two months, so a year of semaglutide is closer to $3,300 than the headline suggests. Use the free consultation to get the post-discount price in writing.
Ask whether the medication is compounded or brand-name. The grouped product names make it impossible to tell, and the price strongly suggests compounded.
Alternatives
knownwell and Circle Medical also combine in-person clinics with insurance billing. Ozari Health is cheaper if you want compounded by mail. Hone Health prices its cheaper generics openly. Our GLP-1 cost guide covers what to expect over a year.
Limitations of This Review
Based on Way Less Weight Loss’s own published materials at waylessweightloss.com, checked on 6 September 2026. Annual totals are our arithmetic from the published monthly prices. Our inference that the advertised GLP-1s are compounded is drawn from the price level and is explicitly an inference — the site does not state the regulatory status either way, which is why we recommend asking. The patient account regarding body composition scanning is a testimonial published on the site; we do not know that person’s clinical picture and make no claim about whether treatment was appropriate in their case. Standard semaglutide titration schedules and shortage resolution dates come from published labelling and FDA materials, not from Way Less. Nothing here is medical advice.
Frequently Asked Questions
Is semaglutide really $150 a month?
For two months, at the 0.25 mg and 0.5 mg doses only. That is the standard titration period, after which the price reverts to $275. A full year is closer to $3,300 than the headline implies.
Would I be getting Ozempic or compounded semaglutide?
The site groups both under one product line and does not say. At these prices it is almost certainly compounded — brand-name Wegovy or Ozempic does not sell at $150 or $275 cash. Ask directly before starting.
Is a body composition scan better than BMI?
It is more informative — BMI cannot distinguish muscle from fat. But the published eligibility criteria and trial evidence for these medications are BMI-based, so if a scan is what makes you eligible, ask what specifically justifies treatment in your case.
Does it take insurance?
It lists Blue Cross, UnitedHealthcare, Ambetter, Aetna, Cigna, Anthem and Humana among others. Whether your plan covers the medication itself is a separate question decided by your pharmacy benefit.
Verdict
3.0 / 5 — $150 for two months, then $275; tirzepatide from $225
A real clinic with real insurance and an unusually broad medication menu — undermined by a headline price scoped to the titration window and product lines that make brand and compounded indistinguishable.
The point worth carrying beyond this provider: read the asterisk on any GLP-1 introductory offer for which doses it covers, not just how long it lasts. A discount limited to the starting doses is a discount on the phase before the drug does much — and it will expire in the same week your dose becomes therapeutic.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Way Less Weight Loss's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026